Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with a 5-year
survival rate of< 10%. The tumour microenvironment (TME) of PDAC is characterized by …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor
prognosis. The lack of early diagnosis and the absence of suitable biomarkers coupled with …

Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading
cause of cancer death by 2030. Current therapeutic options are limited, warranting an urgent …

Pancreatic ductal adenocarcinomas (PDA) are extremely aggressive cancers and currently
available therapies are only minimally effective in treating this disease. Tackling this …

How do cancer cells escape tightly controlled regulatory circuits that link their proliferation to
extracellular nutrient cues? An emerging theme in cancer biology is the hijacking of normal …

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival
rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only …

Pancreatic ductal adenocarcinoma (PDAC) causes annually well over 400,000 deaths world-
wide and remains one of the major unresolved health problems. This exocrine pancreatic …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its highly reactive
inflammatory desmoplastic stroma with evidence of an extensive tumor stromal interaction …

Pancreatic ductal adenocarcinoma (PDA) is an aggressive cancer that is highly refractory to
the current standards of care. The difficulty in treating this disease is due to a number of …

Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid
tumours and poses an unsolved problem in cancer medicine. Despite the recent success of …